Genmab A/S (NASDAQ:GMAB) Shares Bought by Cerity Partners LLC

Cerity Partners LLC boosted its stake in shares of Genmab A/S (NASDAQ:GMAB) by 344.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 55,053 shares of the company’s stock after purchasing an additional 42,661 shares during the quarter. Cerity Partners LLC’s holdings in Genmab A/S were worth $1,753,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Custom Index Systems LLC acquired a new stake in shares of Genmab A/S during the 4th quarter valued at about $410,000. Sequoia Financial Advisors LLC grew its position in shares of Genmab A/S by 93.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 42,364 shares of the company’s stock valued at $1,349,000 after acquiring an additional 20,514 shares during the period. Pinnacle Bancorp Inc. grew its position in shares of Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock valued at $27,000 after acquiring an additional 638 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Genmab A/S during the 4th quarter valued at about $393,000. Finally, Advisors Preferred LLC acquired a new stake in shares of Genmab A/S during the 4th quarter valued at about $82,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $28.70 on Friday. The company has a 50 day simple moving average of $29.38 and a 200-day simple moving average of $30.30. The company has a market capitalization of $18.98 billion, a P/E ratio of 29.90, a P/E/G ratio of 2.05 and a beta of 0.99. Genmab A/S has a 1 year low of $26.32 and a 1 year high of $42.72.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The firm had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. As a group, research analysts expect that Genmab A/S will post 1.06 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on GMAB. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Truist Financial reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, April 4th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and raised their price target for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Finally, Citigroup lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Genmab A/S currently has an average rating of “Hold” and an average target price of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.